Successful psychiatric treatment should leave room for a healthier body. The growing GLP-1 evidence in schizophrenia brings metabolic outcomes into the same conversation as sustained symptom control. Its importance is not that weight has suddenly become relevant, but that randomized studies now address people often missing from general obesity trials.
Start with the psychiatric treatment that is working
Weight gain and dysglycemia can create a painful trade-off for someone who has finally gained stability. Framing the discussion as a failure of willpower misses both the treatment context and the patient’s priorities. The 2017 liraglutide trial in clozapine- or olanzapine-treated adults with prediabetes and overweight or obesity showed that glucose tolerance and weight could improve through an adjunctive metabolic intervention in a population directly relevant to psychiatry. [1]
This is a different question from whether to replace an effective antipsychotic. It asks whether physical health can improve while psychiatric treatment continues. For a clinical conversation, define the metabolic problem, its trajectory and the person’s goals separately from the decision about ongoing antipsychotic treatment. Conflating them can turn an opportunity for coordinated care into an unnecessary threat to continuity. [1]
HISTORI: a larger, directly relevant trial
HISTORI randomized 154 adults with schizophrenia, prediabetes and overweight or obesity who were receiving second-generation antipsychotics. Over 30 weeks, semaglutide produced a between-group reduction in body weight of 9.21 kg and an HbA1c improvement of 0.46 percentage points. The selected population and the primary glycemic outcome are central to interpreting those numbers; they are not expected results for every person with schizophrenia. [2]
The study also assessed psychiatric symptoms and quality of life. Its metabolic findings do not mean that semaglutide replaces antipsychotic treatment or directly treats psychosis. Likewise, a favorable average psychiatric trajectory cannot guarantee stability for an individual. The trial is most useful as evidence that a defined metabolic intervention can be studied alongside continuing psychiatric care, with both physical and mental outcomes observed. [2]
COaST: promising findings with clozapine, in a small sample
The Australian COaST trial addressed an especially important group: people taking clozapine who had obesity. Thirty-one participants were randomized, fewer than the planned recruitment target because investigational-product availability interrupted enrollment. At 36 weeks, the semaglutide group had substantially greater percentage weight loss than placebo. The report found no between-group difference in clozapine or norclozapine concentrations or PANSS scores. [3]
The strength is the direct relevance to clozapine treatment; the limitation is the small sample. A reassuring observation about concentrations does not remove the need to consider interactions, changing health status or the effects of gastrointestinal illness in an individual. Nor can a trial of this size establish the frequency of rare adverse effects. It is a compelling reason for larger confirmatory studies rather than a universal treatment instruction. [3]
The 2026 question: can metabolic problems be addressed earlier?
A further randomized study examined early-stage glycemic abnormalities in people receiving clozapine or olanzapine, with treatment initiated within the preceding five years. Seventy-three participants were randomized and 57 completed the 26-week trial. Improvements in glycemic and weight outcomes broaden the discussion beyond long-established obesity, while the enrollment criteria and completion rate remain important when considering applicability. [4]
Earlier intervention is an attractive principle, but prevention and treatment of established metabolic abnormalities are not interchangeable study questions. The entry HbA1c range, baseline weight, duration of antipsychotic exposure and concurrent care may all differ. An evidence review should therefore preserve these distinctions instead of pooling every favorable weight result into a single promise about prevention. [4]
New treatments should sharpen the prevention conversation
The evidence-based metformin prevention guideline uses a different clinical frame: reducing antipsychotic-associated weight gain early, rather than waiting for severe metabolic deterioration. It was developed with formal guideline methods and consensus validation. Its existence is a reminder that enthusiasm for GLP-1 drugs should not make earlier, potentially more accessible approaches disappear from clinical discussion. [5]
Cross-trial comparisons do not identify a single best strategy. A prevention study, an obesity treatment trial and an established-diabetes indication involve different populations and objectives. Affordability, nutritional support, the ability to attend follow-up and a person’s willingness to continue treatment can change the practical value of an intervention. These considerations deserve explicit discussion, particularly where the cost of long-term care is borne directly by patients and families.
Gastrointestinal symptoms need context in psychiatric care
Semaglutide product information includes gastrointestinal adverse effects, pancreatitis and gallbladder warnings, dehydration-related renal concerns, pregnancy considerations and other restrictions. Delayed gastric emptying also matters when reviewing oral medicines and procedures involving anesthesia. Product formulations and approved indications differ: findings from an injectable research protocol should not be silently transferred to another formulation or product. [6]
For someone receiving clozapine, bowel symptoms deserve particular clinical attention rather than being dismissed as a routine inconvenience. The relevant task is a coordinated review of the whole regimen, current symptoms and medical risk factors. This article does not specify an initiation or escalation schedule; those decisions depend on the exact product, clinical assessment and local requirements. [6]
The outcomes that should define the next phase
A shorter trial can establish a change in weight or glycemia without establishing long-term cardiovascular benefit in the same psychiatric population. It can also leave questions about discontinuation, nutritional effects, access and persistence unresolved. Future studies and service evaluations should measure how treatment fits into ordinary care, including psychiatric engagement and the experience of people who stop treatment.
The practical advance is the ability to discuss metabolic health using evidence that includes people with serious mental illness. The next step is a care model that preserves effective psychiatric treatment, identifies physical-health problems early and makes the follow-up plan workable. A medicine can be an important part of that model; a meaningful result still depends on the surrounding care. [5]
Sources & study types
- Larsen et al. Liraglutide in clozapine- or olanzapine-treated schizophrenia. JAMA Psychiatry (2017).Randomized clinical trial · Accessed 27 October 2026
- HISTORI: semaglutide in antipsychotic-treated schizophrenia, prediabetes and obesity. JAMA Psychiatry (2025).30-week randomized trial · Accessed 27 October 2026
- Siskind et al. COaST: semaglutide with clozapine. The Lancet Psychiatry (2025).36-week phase 2 randomized trial · Accessed 27 October 2026
- Semaglutide and early-stage metabolic abnormalities in schizophrenia spectrum disorders. JAMA Psychiatry (2026).26-week randomized trial · Accessed 27 October 2026
- Carolan et al. Metformin for prevention of antipsychotic-induced weight gain. Schizophrenia Bulletin (2025; online 2024).Evidence-based guideline and consensus · Accessed 27 October 2026
- Wegovy. Current US prescribing information, DailyMed.Official product information · Accessed 27 October 2026
About this review
- Research checked
- 27 October 2026
- Clinical review
- Not independently reviewed
- Method
- Focused narrative review of selected primary studies and official guidance; not a systematic review.
International evidence is discussed in its source context. Indian authorization, availability and individual clinical decisions require separate assessment.